Adare Pharma Solutions

Adare Pharma Solutions

Adare Pharma Solutions is a global contract development and manufacturing organization (CDMO) specializing in oral dosage forms. The firm operates seven facilities across the US and Europe, with a track record of developing and manufacturing more than 65 products sold in over 100 countries. The company's expertise lies in taste masking, customized release, multiparticulate systems, and solubility enhancement for small molecule drugs. Adare's service offering spans the entire drug development lifecycle, from Phase I clinical trials through commercial-scale production and packaging. The firm's proprietary technology platforms include Advatab (oral disintegration), Diffutab and Diffucaps (customized release), Microcaps (taste masking), and Stratum (injectable micro-encapsulation). Key facilities include a 179,000 sq ft R&D and commercial manufacturing center in Vandalia, Ohio; a 220,000 sq ft facility in Pessano, Italy; and 175,000 sq ft of packaging capacity in Philadelphia, Pennsylvania. The company's manufacturing capabilities extend to controlled substances (DEA Schedules II-V) and high-potency compounds. Adare employs a team of over 1,000 professionals across its global network. In March 2026, the firm partnered with Achieve Life Sciences for manufacturing of cytisinicline, a smoking-cessation drug candidate. The company also completed a packaging and warehousing expansion in Europe in October 2025, adding a purpose-built packaging hall and high-speed blistering line at its Milan site. Adjacent vehicles include the Adare Pharmaceuticals foundation, which supports patient access to medications. Adare's structural differentiator is its specialization in solving complex oral formulation challenges that larger, generalist CDMOs often avoid. The firm holds proprietary microencapsulation and multiparticulate technologies that address taste-masking, customized release, and solubility — niches that require deep chemistry expertise. This focus allows Adare to command premium pricing and maintain long-term relationships with pharmaceutical partners whose products depend on these specific capabilities.